Cardiol Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CRDL Nasdaq 2836 www.cardiolrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cardiol Therapeutics Inc.

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - Dec 19th, 2024 1:30 pm
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 - Nov 18th, 2024 4:37 pm
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - Nov 13th, 2024 1:00 pm
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Oct 22nd, 2024 10:30 am
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option - Oct 11th, 2024 12:39 pm
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares - Oct 10th, 2024 1:09 pm
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Oct 9th, 2024 11:58 am
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares - Oct 8th, 2024 8:01 pm
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis - Sep 24th, 2024 11:27 am
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Sep 10th, 2024 11:27 am
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate - Jul 12th, 2024 2:15 pm
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders - Jun 27th, 2024 4:29 pm
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT - Jun 25th, 2024 11:27 am
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients - Jun 17th, 2024 12:20 pm
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis - Jun 13th, 2024 11:58 am
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 - May 14th, 2024 11:27 am
Cardiol Therapeutics Announces Year-End 2023 Update on Operations - Apr 2nd, 2024 10:00 am
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis - Feb 21st, 2024 12:27 pm
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis - Feb 15th, 2024 12:27 pm
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market - Jan 24th, 2024 12:27 pm